Annual influenza vaccination is an important strategy for preventing seasonal infl uenza virus infections and their potentially severe complications, including death. Vaccination reduces the likelihood of acquiring and transmitting infl uenza infections (1) . The annual inactivated infl uenza vaccine (IIV) is safe to administer as an injection to both children and adults (2) . Minor side effects include self-limited reactions at the injection site such as pain, redness, and swelling (2) . Systemic events, such as mild and self-limited fever, malaise, and myalgia, can occur after the IIV has been administered. In some cases, fewer instances of ocular or respiratory symptoms, immediate hypersensitivity, increased risk for febrile seizures in young children, and temporally associated Guillain-Barré Syndrome have been reported (2) . Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disease of the central nervous system (3) . Its onset is acute and often rapidly progressive (4) . It is traditionally monophasic, but some patients may have recurrences. ADEM typically presents with multifocal neurological signs, including motor, sensory, cranial nerve, and brainstem defi cits, as well as nonspecifi c symptoms such as headache, malaise, and altered mental status (i.e., encephalopathy) (4) . The diagnosis is supported by the presence of one or more supratentorial or infratentorial demyelinating lesions on brain magnetic resonance imaging (MRI) and the absence of destructive black hole lesions on T1-weighted MRI (4) . Abnormal cerebrospinal fl uid fi ndings such as mild lymphocytic pleocytosis and slightly elevated cerebrospinal fl uid (CSF) protein level are suggestive of ADEM, but not essential for diagnosis.
Prior viral infections (measles, smallpox, and chickenpox) are known risk factors, and ADEM has rarely been reported to be in temporal association with vaccinations. The rate of ADEM cases diagnosed following vaccination in a biologically plausible risk interval is as low as 0.1-0.2 per 100,000 vaccinated individuals of any age (5) . However, it is more common in children. ADEM has been reported following measles, mumps, rubella, smallpox, hepatitis B, and IIV (6) . Severe neurological complications including ADEM associated with influenza vaccination have been sporadically reported from countries with a good surveillance system (7) (8) . Here, we report a case of ADEM following infl uenza vaccination that occurred in the western Brazilian Amazon.
CASE REPORT
We describe a case of neurological complications that occurred during a biologically plausible risk interval following IIV administration in a 27-year-old previously healthy man living in Manaus (State of Amazonas, Brazil). The vaccine was administered six days before symptoms onset as part of the city's immunization campaign in 2012. The patient worked as an administrative staff, had never smoked, and did not report any previous chronic or severe health conditions or infections. There was no travel history or contact with animals or rural areas before the onset of symptoms. He did not show any clear precipitating factors (e.g., infections), and was admitted with symptoms of fever, vomiting, headache, blurred vision, nuchal pain and fl uctuating alertness and normal neurological examination. Under suspicion of bacterial meningitis, a broad-spectrum antibiotic (meropenem) was prescribed, but he showed no clinical improvement despite intravenous administration every 8 h for 14 days. He was hospitalized for 25 days from the day of symptoms onset.
The patient developed progressive weakness in all four limbs eight days post-vaccination. Neurological signs and symptoms progressed until he was unable to walk, and were associated with urinary retention, constipation, and paresthesia over the trunk and legs. The CSF was colorless with 85 white cells/μL, (normal range: 0-5 cells/μL), 100% lymphocytes, 149.82 mg/dL CSF protein (normal range: 15-60 mg/dL), and 63 mg/dL glucose (normal range: 50-80 mg/dL). His CSF was subjected to Gram staining, Ziehl-Neelsen staining for Mycobacterium tuberculosis, and nankin staining for fungi. The CSF was also subjected to polymerase chain reaction (PCR) to test for Flaviviruses and the results were negative for all (dengue, yellow fever, Ilheus, Rocio, and Saint Louis encephalitis viruses). Fluid-attenuated inversion-recovery (FLAIR) and T2-weighted MRI images revealed brain and spinal cord lesions ( Figure 1A and 1B) . Thick blood smear was negative for Plasmodium spp. Serology tests were negative for human immunodefi ciency virus 1 (HIV-1), viral hepatitis, rubella immunoglobulin M (IgM), and rubella immunoglobulin G (IgG). Respiratory viruses (adenovirus, influenza A1, influenza B, parainfluenza, and respiratory syncytial virus) were tested for using a nasopharyngeal swab and all were negative. No antinuclear antibodies, rheumatoid factor, and alpha fetoprotein were detected in the serum.
Cranial MRI showed multiple hyperintense lesions on T2 and FLAIR, and they involved the periventricular and subcortical white matter, as well as large areas of the medulla oblongata and pons and the splenium of the corpus callosum, bilaterally and asymmetrically. Cervical and dorsal spine MRI revealed focal areas of abnormal signal density with contrast enhancement, and these were randomly distributed on the sides of the cervical-dorsal cord that runs from the brainstem-spinal transition to the cone. The joint analysis of the MRI of the brain and spinal cord indicated ADEM. Based on the temporal association, exclusion of alternative etiologies, neurological fi ndings, and MRI displaying diffuse white matter lesions, we diagnosed our patient's condition to be ADEM following infl uenza vaccination. In the hospital, the patient was treated with intravenous methylprednisolone (500 mg daily for fi ve consecutive days), intravenous immunoglobulin (2,500 mg/kg daily for five consecutive days), and vitamins B and C. After being discharged, he received a second cycle of intravenous methylprednisolone at the same dose and physiotherapy at home (2h/day for 2 months and 1h daily thereafter). The one-month follow-up MRI revealed resolution of the brain lesions (Figure 2A ), but not of the spinal cord, which were suggestive of infl ammation ( Figure 2B) . The last spinal MRI performed four months after symptoms onset showed resolution of the lesions (Figure 2C) . After two years of monitoring, neurological examination showed the persistence of paraparesis and paresthesia in the lower limbs, and the patient continued to experience weakness in his lower limbs and urinary retention. No recurrence or progression of symptoms was seen, suggesting a monophasic episode that ruled out multiple sclerosis. Acute disseminated encephalomyelitis has no pathognomonic clinical features. However, a combination of neurological symptoms in particular temporally associated with an infection or vaccination should alert the clinician of a possible diagnosis of ADEM (5) . Its clinical presentation includes fever, altered consciousness, and multifocal neurological fi ndings. Symptom onset is usually rapid with progression over hours to a peak in days. Focal presentation in ADEM is rather heterogeneous and depends upon the location and degree of demyelination within the central nervous system. MRI is essential for ADEM diagnosis; diffuse or multifocal white matter lesions on FLAIR or T2-weighted sequences are characteristic of ADEM (4) . Lumbar puncture may reveal lymphocytic pleocytosis or elevated protein level. Abnormal CSF is suggestive of ADEM, but not a requisite for diagnosis.
Based on the MRI fi ndings and on excluding acute infective condition, we hypothesized that the IIV might have been related to ADEM in our patient. We then applied the causality criteria to this case, an essential step before diagnosis. According to the World Health Organization (WHO) causality assessment criteria, the association of any event with vaccination is classifi ed as very likely, probable, possible, unlikely, unrelated, or unclassifi able. In the present case, the relationship between infl uenza vaccination and ADEM would be classifi ed as possible (9) . Although the WHO criteria are generally well accepted and widely used, it is important to note that there are signifi cant limitations when applying them to vaccine-related neurological adverse events (10) . A neurological event with a reasonable time relationship to IIV administration is automatically classifi ed as possible, despite the fact that this event could be explained by an underlying disease, pathogens, or other drugs. Following clinical evaluation, the relationship between the same event and vaccination would be classifi ed as unlikely because an alternative condition would explain its occurrence (10) . In the most recent review of vaccine-related adverse events conducted by the Institute of Medicine, it was concluded that there is insuffi cient or lack of epidemiological evidence to either accept or reject a causal association between ADEM and most vaccines, and that the mechanistic evidence based on natural infection is weak (11) . This distinction between temporal coincidence and causality is diffi cult, thus certain causality criteria have been developed. According to the Brighton Collaboration defi nition, the event observed in the present case was ADEM with level 1 (achieved) certainty (12) .
Once ADEM is diagnosed, treatment should begin as soon as possible. Most patients with ADEM improve with treatment, but complete recovery occurs in only 10-46% patients, with motor defi cits and/or cognitive impairment often persisting in the remainder. In fulminant cases, death may occur in 4-12% patients. Corticosteroids are accepted as fi rst-line therapy (3) . For steroid-unresponsive patients, plasma exchange or intravenous immunoglobulin may be used. Poor outcome of treatment is associated with older age, female sex, degree of functional impairment at clinical onset, CSF protein level, spinal cord involvement, peripheral nervous system damage, and poor response to corticosteroids (5) . A few patients may either have recurrences that respond to glucocorticoid therapy or are at risk for development of multiple sclerosis. Our fi ndings underscore the need to consider ADEM when a patient presents with neurological symptoms after infl uenza vaccination, which is usually administered annually to children and adults in many countries. In our patient, the symptoms and signs compatible with ADEM presented with a reasonable time relationship after IIV administration.
